Skip to main content
. 2020 Aug 18;4(16):3886–3893. doi: 10.1182/bloodadvances.2020001942

Table 3.

AEs, AEs ≥grade 3 and serious AEs, and AEs of special interest

Preferred term Ofatumumab (n = 217) Rituximab (n = 218)
AEs (≥10% in either arm), n (%)
 Any event 202 (93) 183 (84)
 Infusion-related reaction 45 (21) 19 (9)
 Rash 42 (19) 11 (5)
 Urticaria 41 (19) 3 (1)
 Fatigue 21 (10) 29 (13)
 Diarrhea 21 (10) 15 (7)
 Nasopharyngitis 14 (6) 22 (10)
 White blood cell count decreased 12 (6) 23 (11)
 Pyrexia 9 (4) 22 (10)
AEs ≥ grade 3 (≥5% of patients), n (%)
 Any event 81 (37) 60 (28)
 Urticaria 16 (7) 0 (0)
 Infusion-related reaction 11 (5) 0 (0)
 Neutropenia 4 (2) 12 (6)
Serious AEs (≥1% of patients), n (%)
 Any event 38 (18) 37 (17)
 Infusion-related reaction 5 (2) 0 (0)
 Pneumonia 2 (< 1) 5 (2)
 Sepsis 1 (< 1) 3 (1)
AEs of special interest (≥1% of patients), n (%)
 Infusion-related AEs 178 (82) 112 (51)
 Infection-related AEs 69 (32) 81 (37)
 Cardiac events 15 (7) 8 (4)
 Neoplasms 13 (6) 7 (3)
 Muco-cutaneous reactions 125 (58) 49 (22)
 Tumor lysis syndrome 3 (1) 0 (0)